242 related articles for article (PubMed ID: 25326347)
1. Long-term outcomes of combined androgen blockade therapy in stage IV prostate cancer.
Matsuoka T; Kawai K; Kimura T; Kojima T; Onozawa M; Miyazaki J; Nishiyama H; Hinotsu S; Akaza H
J Cancer Res Clin Oncol; 2015 Apr; 141(4):759-65. PubMed ID: 25326347
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer.
Kitagawa Y; Ueno S; Izumi K; Kadono Y; Mizokami A; Hinotsu S; Akaza H; Namiki M
World J Urol; 2016 Mar; 34(3):319-27. PubMed ID: 26089252
[TBL] [Abstract][Full Text] [Related]
3. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a Japanese perspective--the effect of primary androgen deprivation therapy on stage C prostate cancer.
Akaza H
BJU Int; 2007 Jan; 99 Suppl 1():10-2; discussion 17-8. PubMed ID: 17229161
[TBL] [Abstract][Full Text] [Related]
4. Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database.
Beebe-Dimmer JL; Ruterbusch JJ; Bylsma LC; Gillezeau C; Fryzek J; Schultz NM; Flanders SC; Barlev A; Heath E; Quek RGW
Adv Ther; 2018 Sep; 35(9):1438-1451. PubMed ID: 29946798
[TBL] [Abstract][Full Text] [Related]
5. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL.
Kashiwabara T; Suda S
BMC Cancer; 2018 May; 18(1):619. PubMed ID: 29855278
[TBL] [Abstract][Full Text] [Related]
7. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival.
Akaza H; Hinotsu S; Usami M; Arai Y; Kanetake H; Naito S; Hirao Y;
Cancer; 2009 Aug; 115(15):3437-45. PubMed ID: 19536889
[TBL] [Abstract][Full Text] [Related]
8. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?
Labrie F; Candas B; Gomez JL; Cusan L
Urology; 2002 Jul; 60(1):115-9. PubMed ID: 12100935
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
10. Combined androgen blockade (CAB) versus luteinizing hormone-releasing hormone (LHRH) agonist monotherapy for androgen deprivation therapy.
Park HS; Shin HB; Woo SH; Jeon SH; Lee SH; Kang SH; Shim JS; Shin DW; Park J
World J Urol; 2020 Apr; 38(4):971-979. PubMed ID: 31187203
[TBL] [Abstract][Full Text] [Related]
11. Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community-based multi-institutional database across Japan using propensity score matching.
Onozawa M; Akaza H; Hinotsu S; Oya M; Ogawa O; Kitamura T; Suzuki K; Naito S; Namiki M; Nishimura K; Hirao Y; Tsukamoto T
Cancer Med; 2018 Oct; 7(10):4893-4902. PubMed ID: 30151999
[TBL] [Abstract][Full Text] [Related]
12. Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy.
Kadono Y; Nohara T; Ueno S; Izumi K; Kitagawa Y; Konaka H; Mizokami A; Onozawa M; Hinotsu S; Akaza H; Namiki M
World J Urol; 2016 Feb; 34(2):261-7. PubMed ID: 26047654
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of primary combined androgen blockade for Japanese men with clinically localized prostate cancer unsuitable for local definitive treatment: a single institution experience.
Kobayashi M; Nukui A; Suzuki K; Kurokawa S; Morita T
Int J Clin Oncol; 2011 Dec; 16(6):630-6. PubMed ID: 21512893
[TBL] [Abstract][Full Text] [Related]
14. A single-center study on predicting outcomes of primary androgen deprivation therapy for prostate cancer using the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score.
Yamaguchi Y; Hayashi Y; Ishizuya Y; Takeda K; Nakai Y; Arai Y; Nakayama M; Kakimoto K; Nishimura K
Jpn J Clin Oncol; 2015 Feb; 45(2):197-201. PubMed ID: 25381383
[TBL] [Abstract][Full Text] [Related]
15. Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.
Kitagawa Y; Hinotsu S; Shigehara K; Nakashima K; Kawaguchi S; Yaegashi H; Mizokami A; Akaza H; Namiki M
Int J Urol; 2013 Jul; 20(7):708-14. PubMed ID: 23216462
[TBL] [Abstract][Full Text] [Related]
16. Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer.
Cooperberg MR; Hinotsu S; Namiki M; Carroll PR; Akaza H
BJU Int; 2016 Jan; 117(1):102-9. PubMed ID: 25238114
[TBL] [Abstract][Full Text] [Related]
17. Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP.
Hinotsu S; Akaza H; Usami M; Ogawa O; Kagawa S; Kitamura T; Tsukamoto T; Naito S; Namiki M; Hirao Y; Murai M; Yamanaka H;
Jpn J Clin Oncol; 2007 Oct; 37(10):775-81. PubMed ID: 17965423
[TBL] [Abstract][Full Text] [Related]
18. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
Soga N; Arima K; Sugimura Y
Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
[TBL] [Abstract][Full Text] [Related]
19. A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial.
Kamba T; Kamoto T; Maruo S; Kikuchi T; Shimizu Y; Namiki S; Fujimoto K; Kawanishi H; Sato F; Narita S; Satoh T; Saito H; Sugimoto M; Teishima J; Masumori N; Egawa S; Sakai H; Okada Y; Terachi T; Ogawa O;
Int J Clin Oncol; 2017 Feb; 22(1):166-173. PubMed ID: 27614621
[TBL] [Abstract][Full Text] [Related]
20. Oncological outcomes of hormonal therapy with a gonadotropin-releasing hormone agonist combined with a steroidal or non-steroidal antiandrogen in patients with prostate cancer.
Igawa T; Tsurusaki T; Nomata K; Hayashi M; Furukawa M; Sakai H
Anticancer Res; 2014 Apr; 34(4):1983-8. PubMed ID: 24692735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
